EP1443944A1 - Applications pharmaceutiques de preparations a l'acide hyaluronique - Google Patents

Applications pharmaceutiques de preparations a l'acide hyaluronique

Info

Publication number
EP1443944A1
EP1443944A1 EP02779554A EP02779554A EP1443944A1 EP 1443944 A1 EP1443944 A1 EP 1443944A1 EP 02779554 A EP02779554 A EP 02779554A EP 02779554 A EP02779554 A EP 02779554A EP 1443944 A1 EP1443944 A1 EP 1443944A1
Authority
EP
European Patent Office
Prior art keywords
hyaluronic acid
use according
heparin
carriers
application
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02779554A
Other languages
German (de)
English (en)
Inventor
Johannes Reinmüller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10209966A external-priority patent/DE10209966A1/de
Application filed by Individual filed Critical Individual
Publication of EP1443944A1 publication Critical patent/EP1443944A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations

Definitions

  • the present invention relates to new applications of pharmaceutical compositions which contain crosslinked or uncrosslinked and preferably long-chain hyaluronic acid and conventional pharmaceutical auxiliaries and / or carriers.
  • One aspect relates to the use of a composition containing hyaluronic acid associated with heparin for the delayed release of heparin, e.g. with wound, scar and keloid treatment, to inhibit blood clotting or to relieve pain.
  • Another aspect of the invention relates to the use of a pharmaceutical composition containing hyaluronic acid for the treatment of viral infections, in particular for the treatment of an infection with herpes viruses.
  • Yet another aspect of the invention relates to the use of a pharmaceutical composition containing hyaluronic acid as an analgesic, in particular for application in the area of nerve endings.
  • a pharmaceutical composition containing hyaluronic acid for tightening skin, in particular for permanently reducing wrinkles in the facial area.
  • Hyaluronic acid is a non-sulfated glycosaminoglycan that occurs in the human body in synovial fluid and in extracellular matrices. It is widely used as a building block for biocompatible and biodegradable polymers in various medical applications.
  • European patent 061 9737 relates to a pharmaceutical composition for non-topical wound, scar and keloid treatment, which comprises one or more cross-linked glycosaminoglycans and contains conventional pharmaceutical auxiliaries and / or carriers.
  • glycosaminoglycans include hyaluronic acid and heparin.
  • crosslinked glycosammoglycans with other active pharmaceutical ingredients, such as antibiotics is disclosed.
  • the crosslinked or uncrosslinked hyaluronic acid preferably long-chain hyaluronic acid
  • heparin preferably with short-chain heparin, which has a chain length of e.g. Has 5 to 10 saccharide units
  • the hyaluronic acid serves as a matrix to enable a controlled release of heparin. The rate of release can be controlled via the degree of crosslinking and the type of crosslinking of the hyaluronic acid as well as the type of heparin and its association with the hyaluronic acid.
  • composition according to the invention has an inhibiting effect on keloid formation, in particular when it is applied non-topically (intralesionally).
  • scars of all kinds including deep scarring in the connective tissue, such as e.g. successfully treat the Dupuytren's disease of the palms or the so-called Induratio penis plastica (IPP), which arise without previous injury (continuity separation).
  • IPP Induratio penis plastica
  • the composition has a number of advantages over known preparations. A largely pain-free administration by injection is thus possible. There are also no local overreactions and no undesirable systemic side effects. Another advantage is the biodegradability in the organism.
  • composition is also suitable for other known pharmaceutical applications of heparin, both for systemic and local applications, e.g. to inhibit blood clotting.
  • composition can also be applied in the form of an implant by surgical methods.
  • Subcutaneous administration of the preparation to patients for thromboprophylaxis could be carried out largely painlessly.
  • the administration was repeated several times at 7 day intervals.
  • the hyaluronic acid can be used in uncrosslinked or crosslinked, for example covalently or non-covalently, crosslinked form.
  • the crosslinked hyaluronic acid can be produced in a known manner.
  • the covalent crosslinking is generally carried out by crosslinking with bifunctional reactive agents, such as, for example, glutaraldehyde or carbodiimide; via bifunctional amino acids, for example lysine, protamines or albumins.
  • cross-links can also be produced via an amide bond, for example.
  • Suitable reagents for the covalent crosslinking of hyaluronic acid are ethylene glycol or 1,4-butanediol diglycidyl ether, divinyl sulfone, photocrosslinking reagents such as ethylosine, hydrazides such as bishydrazide, trishydrazide and polyvalent hydrazide compounds. Intramolecular and / or intermolecularly esterified hyaluronic acid derivatives can also be used.
  • Non-covalent crosslinking using polyvalent metal ions such as iron, copper, zinc, calcium, magnesium, barium and other chelating metal ions is particularly preferred.
  • Hyaluronic acid is commercially available in the crosslinked state and can then be used according to the invention by association with heparin (for example, Hylon ® and Hylagel ®, a cross-linked hyaluronic acid of the company biomatrix, NJ, USA;.. See for producing also US 471 3448, US -A-4605691, APC ® from. Fidia, Incert ® from. Anika Therapeutics or Intergel ® from. Lifecore).
  • heparin for example, Hylon ® and Hylagel ®, a cross-linked hyaluronic acid of the company biomatrix, NJ, USA;.. See for producing also US 471 3448, US -A-4605691, APC ® from. Fidia, Incert ® from. Anika Therapeutics or Intergel ® from. Lifecore).
  • long-chain hyaluronic acid (molecular weight preferably between 10 4 and 10 6 Da, in particular between 10 5 and 10 6 Da) is used; the degree of crosslinking can then remain low. If the degree of crosslinking is higher, short-chain hyaluronic acid is also suitable, it also being possible to use molecules with a short chain length of only a few, for example> 10, preferably> 20 saccharide units.
  • the heparin can be associated with the hyaluronic acid covalently or non-covalently, for example by chemical crosslinking or by chelation, as explained above.
  • Physiologically compatible polyvalent metal ions such as Mg 2 + , Ca 2 + , Zn 2 + , Fe 2 + or Fe 3 + , are preferably used for chelation.
  • the pharmaceutical compositions according to the invention preferably contain the hyaluronic acid in amounts of 0.01 to 20% by weight, based on the total pharmaceutical composition, in particular in an amount of 0.01 to 5% by weight and particularly preferably in an amount of 0.01 to 1% by weight.
  • the proportion of heparin in the compositions can be varied in a wide range and depends on the size and type (for example crosslinked and uncrosslinked) of the heparin and its association with the hyaluronic acid and the intended type and duration of use. In general, the proportion is in the range from 0.1 to 20% by weight, based on the overall pharmaceutical composition, in particular from 0.5 to 10% by weight and particularly preferably from 1 to 5% by weight.
  • the heparin can be in long-chain or short-chain, crosslinked or uncrosslinked form. Short-chain heparin with a size of 5-50, in particular 5-10, saccharide units is preferably used.
  • compositions according to the invention can be in the form of preparations which can be applied by injection or surgery and in particular in the form of injectable or implantable gels or solutions, preferably with a water content of 60 to 99% by weight, or else as an anhydrous precursor, e.g. lyophilized powder in the form of a powder.
  • anhydrous precursor e.g. lyophilized powder in the form of a powder.
  • customary substances suitable for the application according to the invention and compatible with hyaluronic acid and heparin can be used.
  • the preferred carrier is water or an aqueous buffer solution.
  • compositions according to the invention e.g. Contain pH adjusting agents, stabilizers, antioxidants, solubilizers, penetration enhancers, preservatives and / or gelling agents, as are commonly used in such compositions. They are used in the amounts customary in such preparations.
  • compositions according to the invention may optionally contain hyaluronic acid plus in addition to the actual active ingredients Heparin also contains other pharmaceutical active ingredients that are compatible with hyaluronic acid and heparin in the context of the application, e.g. active ingredients for the therapy of skin diseases (dermatoses), antibiotics, e.g. gentamycin, vancomycin, penicillins or cephalosporins, sulfonamides, disinfectants, hormones (e.g. corticoids) and hormone derivatives (e.g. cortisol), local anesthetics, e.g.
  • active ingredients for the therapy of skin diseases dermatoses
  • antibiotics e.g. gentamycin, vancomycin, penicillins or cephalosporins
  • sulfonamides e.g. active ingredients for the therapy of skin diseases (dermatoses)
  • antibiotics e.g. gentamycin, vancomycin, penicillins or cephalosporins
  • vasoactive substances for vascular constriction preventing bleeding
  • adrenaline enzymes such as hyaluronidase, interleukins, growth factors, e.g. EGF, PDGF and or IG F, skin care agents and / or blood circulation-promoting (hyperaemic) agents.
  • the further active ingredients can optionally be associated with the hyaluronic acid, for example through covalent or non-covalent interactions.
  • the preparations e.g. to avoid pain when puncturing with the injection cannula, contain local anesthetics.
  • compositions according to the invention can be prepared in a generally known manner which is customary per se for the manufacture of such compositions.
  • the order in which the individual components are mixed is generally not critical.
  • compositions according to the invention depend in particular on the type and severity of the disease and on the general condition of the patient and the condition of the application site, for example the condition and sensitivity of a scar and skin or wound after surgery. If the compositions according to the invention are administered in the form of topically administrable preparations, this corresponds to Administration usually under the conditions customary for such compositions.
  • Gels or solutions are preferably applied at intervals of several days to 1 or 2 months, in particular approximately 1 to 2 weeks.
  • compositions according to the invention are administered intralesonally in the form of injectable gels, this is preferably done by injection with the aid of fine cannulas and with pressure-resistant syringes.
  • the gels according to the invention can also be transdermally injected using pressure devices; pressure devices can be used for this, as are known in medicine for such an application.
  • Certain preparations can also be systemic, i.e. in the circulation or in body cavities, e.g. after surgery.
  • Implantable compositions are preferably in the form of viscous gels or solutions, so-called instillation solutions.
  • heparin Due to the association with long-chain hyaluronic acid, uncrosslinked and even short-chain heparin can be applied as an active ingredient by injection. The rapid removal of the heparin from the site of action without the association with hyaluronic acid is avoided by the compositions according to the invention.
  • the heparin remains dependent on the breakdown of the hyaluronic acid matrix and the type of binding for days, weeks or months at the application site, e.g. in keloid tissue, effective.
  • the duration of action is particularly preferably 5-20 days, e.g. about 1-2 weeks.
  • Another form of application for the prevention of keloids or contracted scars is the application of water-free compositions (e.g. as a lyophilisate) in the form of a wound powder in fresh wounds or body cavities.
  • the powder is sprinkled into the open wound or wound cavity before the wound is closed. Then the wound is closed by suturing, by staples or the like.
  • the powder absorbs water from the tissue in the wound and then corresponds to the preparation according to the invention in the form of a gel or is itself a preparation according to the invention.
  • compositions in powder or gel form can also be introduced into large body cavities to prevent unwanted adhesions, e.g. into the abdominal or chest cavity, during a surgical operation on the intestine or on the lungs, in the pericardium, or after surgery on drainage.
  • the preparation according to the invention can also be introduced via the lying cannula after puncture and emptying of the effusion.
  • the preparation according to the invention can also be introduced into cavities and passages of the body which are accessible from the outside, for example into the nasal and paranasal sinuses or nasal passages or into the tear ducts to prevent scarred adhesions, possibly also on a suitable carrier (for example a tampon).
  • a suitable carrier for example a tampon.
  • these compositions are intended for the treatment of viral infections, for example in the treatment of infections with neurotropic viruses, such as herpes viruses, for example herpes simplex or herpes zoster.
  • neurotropic viruses such as herpes viruses, for example herpes simplex or herpes zoster.
  • the application can be local or systemic.
  • the composition is preferably used for the treatment of dermal or mucosal herpes infections, for example herpes labialis or genital herpes.
  • hepatotropic viruses such as hepatitis viruses, for example hepatitis A, B, C viruses
  • immunotr ⁇ pen viruses for example HIV, cytomegalovirus
  • other neurotropic viruses for example polio
  • Infections with other viruses can also be treated which cause diseases of the eyes, for example keratoconjunctivitis epidemica, or the respiratory tract, for example colds, runny nose or flu.
  • examples of such viruses are rhino and influenza viruses.
  • local, for example topical or transdermal application is preferred.
  • compositions or compositions for nasal administrations for example drops, sprays and inhalable aerosols.
  • the composition can also be administered systemically, for example by intravenous injection or orally as a drinking or rinsing solution, for example for combating infections of the gastrointestinal tract or throat.
  • Single or multiple prophylactic administration before the onset of an acute illness is particularly preferred.
  • the composition was administered in the form of a gel by intra- or subdermal injection into the affected area in patients with recurrent herpes labialis, it was found that the onset of the infection could at least be largely prevented.
  • the patients were free from fluorescence. Administration in the prodromal stage was particularly effective when itching occurred. If necessary, the administration of the composition can be repeated prophylactically at longer intervals, for example of 3 months.
  • compositions containing hyaluronic acid are use as an analgesic, preferably as a peripheral analgesic, in particular for application in the area of nerve endings, e.g. of injured nerve endings, for example after cuts.
  • analgesic preferably as a peripheral analgesic
  • the application can take place locally, for example, by injection.
  • Administration of the composition in surgical wounds, e.g. As a powder, gel or solution before wound closure led to considerable pain relief in several cases and also to a significant reduction in the need for additional peripheral or central pain relievers.
  • compositions containing hyaluronic acid are skin tightening.
  • a lasting effect ie an effect which could be recognized over a period of at least 6 months and in particular over one to several years, could be achieved.
  • the forehead wrinkles were visibly reduced in several patients one year after application of the composition.
  • the compositions are thus suitable as a "lifting serum" for tightening facial skin and can help to avoid surgical procedures for tightening the face.
  • the application is preferably transdermal, for example by injection or with one of the previously described transdermal ' n application systems, and can be carried out selectively and / or extensively on the skin areas to be tightened.
  • Hyaluronic acid can also be added to infiltration solutions that are pre-injected into the tissue before liposuction.
  • infiltration solutions are usually isotonic or hypotonic saline solutions, which may contain additives, for example vasoconstricting and / or pain-reducing additives, such as noradrenaline, adrenaline, lidocaine, prilocaine, bicarbonate, corticosteroids etc.
  • hyaluronic acid crosslinked or / and non-crosslinked in hyaluronic acid
  • hyaluronic acid mechanically facilitates the liposuction process, i.e. handling the suction curette, which is moved through the fatty tissue, requires less effort .; Furthermore, structures of the adipose tissue that are worth preserving, e.g. Blood vessels, nerves or connective tissue tapes, spared. The process of liposuction is also significantly more atraumatic due to the hyaluronic acid additive compared to the conventional procedure. Finally, the hyaluronic acid additive to the infiltration solution improves the flow properties of the fatty tissue aspirate, so that it is possible to work with a lower vacuum. This also leads to a reduction in tissue trauma.
  • hyaluronic acid to the infiltration solution protects the remaining adipose tissue in the organism and gently removes the adipose adipose tissue. This improves the survival of fat cells in the aspirate.
  • adipose tissue aspirates can be used as the body's own grafts.
  • the fat cells are spared when removed, so that in the case of a transplant, there is an increased growth of the transferred tissue is observed at the recipient site.
  • Hyaluronic acid is therefore particularly preferably always added to the infiltration solution when the aspirated fatty tissue is to be transferred to other parts of the body as an autologous graft.
  • An object of the invention is thus a fatty tissue aspirate which contains hyaluronic acid (cross-linked or non-cross-linked).
  • the fat aspirate is particularly preferred for cosmetic purposes, e.g. used to pad soft tissues on the face.
  • the aspirate is inserted into the recipient site through thin cannulas, for example with a diameter of 1-2 mm.
  • the presence of hyaluronic acid in the aspirate or graft facilitates the passage of the tissue through the cannula. This means less application of pressure for transport through the cannula, less traumatization of the transferred tissue and / or a higher rate of growth of the transferred tissue at the recipient site.
  • the fatty tissue aspirate containing hyaluronic acid according to the invention can also be used after conventional suction (without the addition of hyaluronic acid) in a higher concentration, e.g. 0.1-1% (w / o) are added to the fat tissue portion (fraction) of the aspirate to be transferred, which likewise leads to an increased unitization rate of the transferred tissue.
  • a higher concentration e.g. 0.1-1% (w / o) are added to the fat tissue portion (fraction) of the aspirate to be transferred, which likewise leads to an increased unitization rate of the transferred tissue.
  • a hyaluronic acid additive cross-linked and / or non-cross-linked
  • a hyaluronic acid additive improve the survival and / or the growth of the transferred tissue particles or cells.
  • hyaluronic acid also acts as a lubricant and thus also as a protective film for grafts, e.g. in the pericardium, in the pleural space or in the peritoneum, since organs are shifted against each other in these cavities or spaces.
  • Hyaluronic acid can therefore also be used as a lubricant in the above-mentioned gaps.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Birds (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne de nouvelles applications de compositions pharmaceutiques qui contiennent des acides hyaluroniques réticulés ou non réticulés et de préférence à chaîne longue, ainsi que des adjuvants et/ou des supports classiques.
EP02779554A 2001-11-12 2002-11-12 Applications pharmaceutiques de preparations a l'acide hyaluronique Withdrawn EP1443944A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DE10155440 2001-11-12
DE10155440 2001-11-12
DE10209966 2002-03-07
DE10209966A DE10209966A1 (de) 2001-11-12 2002-03-07 Pharmazeutische Anwendungen von Hyaluronsäure-Präparaten
PCT/EP2002/012659 WO2003041723A1 (fr) 2001-11-12 2002-11-12 Applications pharmaceutiques de preparations a l'acide hyaluronique

Publications (1)

Publication Number Publication Date
EP1443944A1 true EP1443944A1 (fr) 2004-08-11

Family

ID=26010552

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02779554A Withdrawn EP1443944A1 (fr) 2001-11-12 2002-11-12 Applications pharmaceutiques de preparations a l'acide hyaluronique

Country Status (3)

Country Link
US (1) US7807656B2 (fr)
EP (1) EP1443944A1 (fr)
WO (1) WO2003041723A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004002001A1 (de) * 2004-01-14 2005-08-11 Reinmüller, Johannes, Dr.med. Mittel zur Behandlung von entzündlichen Erkrankungen
FR2909285A1 (fr) * 2006-12-01 2008-06-06 Anteis Sa "utilisation d'un gel anti-adhesif et anti fibrotique"
JP5722217B2 (ja) * 2008-09-02 2015-05-20 アラーガン・ホールディングス・フランス・ソシエテ・パール・アクシオン・サンプリフィエＡｌｌｅｒｇａｎ Ｈｏｌｄｉｎｇｓ Ｆｒａｎｃｅ Ｓ．Ａ．Ｓ． ヒアルロン酸および／またはその誘導体の糸、その作製方法、ならびにその使用
US9446227B2 (en) 2008-09-12 2016-09-20 Sonescence, Inc. Ultrasonic dispersion of compositions in tissue
US20100069827A1 (en) * 2008-09-12 2010-03-18 Barry Neil Silberg Pre-Surgical Prophylactic Administration of Antibiotics and Therapeutic Agents
US20110172180A1 (en) 2010-01-13 2011-07-14 Allergan Industrie. Sas Heat stable hyaluronic acid compositions for dermatological use
DE102011077393A1 (de) * 2011-06-10 2012-12-13 Johannes Reinmüller Antiinfektives Mittel
CZ2012282A3 (cs) 2012-04-25 2013-11-06 Contipro Biotech S.R.O. Zesítovaný derivát hyaluronanu, zpusob jeho prípravy, hydrogel a mikrovlákna na jeho bázi
US9155757B2 (en) * 2013-10-07 2015-10-13 Laboratoires Vivacy Methods and kits for treating vaginal and vulvar vestibule mucosa disorders
AR099900A1 (es) * 2014-04-01 2016-08-24 Merz Pharma Gmbh & Co Kgaa Rellenos para tejidos blandos con polisacáridos con persistencia mejorada, kit, procedimiento, uso
US20170360815A1 (en) 2016-02-25 2017-12-21 Applied Biological Laboratories, Inc. Compositions and methods for protecting against airborne pathogens and irritants
CA3014764A1 (fr) 2016-02-25 2017-08-31 Applied Biological Laboratories, Inc. Compositions et procedes de protection contre des agents pathogenes et des substances irritantes aeriens
JP2021155334A (ja) * 2018-05-01 2021-10-07 学校法人近畿大学 中分子ヘパリンまたは中分子ヘパリンのアミノ酸誘導体を含む医薬組成物

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4141973A (en) * 1975-10-17 1979-02-27 Biotrics, Inc. Ultrapure hyaluronic acid and the use thereof
US4414973A (en) * 1981-03-10 1983-11-15 U.S.D. Corp. Respirator face mask
US4636524A (en) * 1984-12-06 1987-01-13 Biomatrix, Inc. Cross-linked gels of hyaluronic acid and products containing such gels
NZ222695A (en) * 1986-11-29 1990-03-27 Ueno Seiyaku Oyo Kenkyujo Kk Synergistic antiviral compositions
US4946832A (en) * 1987-03-13 1990-08-07 R.I.T.A. Corporation Cosmetic base composition with therapeutic properties
JPH01321726A (ja) 1988-06-23 1989-12-27 Kawasaki Steel Corp プログラマブル集積回路
US4965071A (en) * 1988-10-19 1990-10-23 The Gillette Company Wrinkle masking composition of sodium polystyrene sulfonate and process for use
CA2056392A1 (fr) * 1989-05-26 1990-11-27 Lawrence T. Maddren Traitement topique du herpesvirus hominis
CA1340994C (fr) * 1989-09-21 2000-05-16 Rudolf Edgar Dr. Falk Traitement de maladies et d'etats pathologiques
JP2919516B2 (ja) * 1989-12-12 1999-07-12 品川燃料株式会社 人工皮膚及びその製造方法
US5290271A (en) * 1990-05-14 1994-03-01 Jernberg Gary R Surgical implant and method for controlled release of chemotherapeutic agents
DE4200080A1 (de) * 1992-01-03 1993-09-30 Reinmueller Johannes Pharmazeutische Zusammensetzung zur Wund-, Narben- und Keloidbehandlung
US5256140A (en) * 1992-03-27 1993-10-26 Fallien Cosmeceuticals, Ltd. Composition for levelling skin
IT1263394B (it) * 1993-07-30 1996-08-05 Fidia Advanced Biopolymers Srl Composizioni farmaceutiche per uso topico a base di acido ialuronico e suoi derivati
US5583120A (en) * 1993-08-04 1996-12-10 Patent Biopharmaceutics, Inc. Hyaluronic acid-urea pharmaceutical compositions and uses
AU3159595A (en) * 1994-08-30 1996-03-22 Hyal Pharmaceutical Corporation Hyaluronic acid and derivatives for modulation of cellular activity
DE19520575A1 (de) * 1995-06-06 1996-12-12 Permselect Ges Fuer Zellstrukt Hautwirksame Kombination von Mucopolysacchariden
US6482806B1 (en) * 1996-03-15 2002-11-19 Takara Shuzo Co., Ltd. Product of heat treatment of uronic acid, food, drink, or drug including the product
CA2217134A1 (fr) * 1996-10-09 1998-04-09 Sumitomo Pharmaceuticals Co., Ltd. Formulation a liberation-retard
GB9700624D0 (en) * 1997-01-14 1997-03-05 Danbiosyst Uk Drug delivery composition
US20020025921A1 (en) * 1999-07-26 2002-02-28 Petito George D. Composition and method for growing, protecting, and healing tissues and cells
US6824793B1 (en) * 1998-06-01 2004-11-30 Chiron Corporation Use of hyaluronic acid polymers for mucosal delivery of vaccine antigens and adjuvants
DE19923829A1 (de) * 1999-05-17 2000-11-23 Ulrich Kluegel Hyaluronat-Wirkstoff-Wasser-Komplex, dessen Herstellung und Verwendung
CN1228054C (zh) * 2000-07-25 2005-11-23 凌沛学 含有透明质酸钠的人工皮肤粉末剂及其制作方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO03041723A1 *

Also Published As

Publication number Publication date
WO2003041723A1 (fr) 2003-05-22
US7807656B2 (en) 2010-10-05
US20050187185A1 (en) 2005-08-25

Similar Documents

Publication Publication Date Title
EP0619737B1 (fr) Composition pharmaceutique pour le traitement de plaies, cicatrices et cheloides
EP1711190B1 (fr) Agent servant a traiter des maladies inflammatoires
DE60116052T2 (de) Polymermischungen als bioabbaubare matrizen zur herstellung von biokompositen
DE3689909T2 (de) Verwendung eines GHL-Cu enthaltenden Stoffes zur Herstellung eines Arzneimittels für Wunden.
DE69936212T2 (de) Hydrogelzusammensetzungen mit kontrollierter Freigabe für die Verabreichung von Wachstumsfaktoren
DE3927113C2 (de) Mittel zur Behandlung von schweren Schmerzzuständen und Verfahren zu ihrer Herstellung
DE69034018T2 (de) Kombinierte verwendung von hyaluronsäure und therapeutischen wirkstoffen zur verbesserung des therapeutischen effekts
DE60030124T2 (de) Hyaluronsäure-ester zur behandlung von normotrophischen hautnarben
EP2099462B1 (fr) Préparation pharmaceutique pour le traitement de pathologies inflammatoires du système urogénital
DE69715586T2 (de) Methoden zur Abdeckung von chirurgischen Eingriffstellen unter Verwendung von Cyanoacrylatester-Zusammensetzungen
DE60027209T2 (de) Behandlung von Knochengewebserkrankungen
DE60112431T2 (de) Verwendung von biguanidederivaten zur herstellung eines vernarbungsfördernden medikaments
EP1443944A1 (fr) Applications pharmaceutiques de preparations a l'acide hyaluronique
DE69328228T2 (de) Wundheilmittel
DE69705110T2 (de) Topische pharmazeutische zusammensetzungen, welche heparin enthalten
EP0285856B1 (fr) Emploi de dihydroergotamine et de ses sels pour le traitement local de troubles trophiques
DE69724798T2 (de) Mannose-6-phosphat enthaltendes mittel und dessen verwendung bei der behandlungfibrotischer erkrankungen
DE3883645T2 (de) Therapeutische Zusamensetzungen und Verfahren zur Verhinderung von Fibrinablagerung und Adhäsionen.
EP2717885A1 (fr) Agent anti-infectieux
DE10209966A1 (de) Pharmazeutische Anwendungen von Hyaluronsäure-Präparaten
WO2000033829A1 (fr) Utilisation de poly (hexamethylene) biguanide pour produire un agent destine a favoriser la guerison de blessures non infectees
MX2013004077A (es) Composicion farmaceutica a base de centella asiatica (hydrocotyle asiatica l.) para el tratamiento de ulceras en miembros inferiores.
WO2023152241A1 (fr) Colestyramine pour le traitement de plaies, d'infections bactériennes de la peau et de lésions cutanées inflammatoires
DE69525728T2 (de) Verminderung des Fettgewebes durch Verwendung von Kollagenase
WO2011012312A1 (fr) Compositions d’instillation de la vessie pour le traitement du cancer de la vessie

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20040511

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

17Q First examination report despatched

Effective date: 20080214

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20131115